India's Drug-Industry Woes No Deterrence To More Than Doubled Market
This article was originally published in PharmAsia News
Despite its U.S. FDA, regulatory and other problems, India's pharmaceutical market is expected to more than double its value over the next seven years, from $21 billion to $56 billion.
You may also be interested in...
India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.